Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Tannock

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Cancer|March 27, 2015
Long-term impact of androgen-deprivation therapy on physical function and quality of lifeShabbir M H Alibhai, Henriette Breunis, Narhari Timilshina, et al.
JAMA Network Open|January 22, 2025
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential CensoringTomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, et al.
JCO Global Oncology|April 15, 2026
Mapping Radiotherapy Resources for Prostate Cancer Trials in Nigeria: A STAMPEDE 2-Site SurveyOmolara Fatiregun, Nwamaka Lasebikan, Onyeanunam Ekeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2010
Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancerShabbir M H Alibhai, Henriette Breunis, Narhari Timilshina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2010
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancerShabbir M H Alibhai, Henriette Breunis, Narhari Timilshina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
BJU International|November 15, 2008
Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancerAbbas H Panju, Henriette Breunis, Angela M Cheung, et al.
Cancer Medicine|October 12, 2022
Cognitive impairment in adolescent and young adult cancer patients: Pre-treatment findings of a longitudinal studyAlexandre Chan, Ivy Cheng, Claire Wang, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 1, 2025
Strategies for Improving Access to Effective Prostate Cancer Medications (Abiraterone and Enzalutamide) in Low- and Middle-Income Countries (LMICs): A Survey Among Nigerian Health ProfessionalsOmolara Fatiregun, Onyeanunam Ekeke, Egbuchilem Chisor-Wabali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Cancer|March 27, 2015
Long-term impact of androgen-deprivation therapy on physical function and quality of lifeShabbir M H Alibhai, Henriette Breunis, Narhari Timilshina, et al.
JAMA Network Open|January 22, 2025
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential CensoringTomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, et al.
JCO Global Oncology|April 15, 2026
Mapping Radiotherapy Resources for Prostate Cancer Trials in Nigeria: A STAMPEDE 2-Site SurveyOmolara Fatiregun, Nwamaka Lasebikan, Onyeanunam Ekeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2010
Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancerShabbir M H Alibhai, Henriette Breunis, Narhari Timilshina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2010
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancerShabbir M H Alibhai, Henriette Breunis, Narhari Timilshina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
BJU International|November 15, 2008
Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancerAbbas H Panju, Henriette Breunis, Angela M Cheung, et al.
Cancer Medicine|October 12, 2022
Cognitive impairment in adolescent and young adult cancer patients: Pre-treatment findings of a longitudinal studyAlexandre Chan, Ivy Cheng, Claire Wang, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 1, 2025
Strategies for Improving Access to Effective Prostate Cancer Medications (Abiraterone and Enzalutamide) in Low- and Middle-Income Countries (LMICs): A Survey Among Nigerian Health ProfessionalsOmolara Fatiregun, Onyeanunam Ekeke, Egbuchilem Chisor-Wabali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.
Pageof 5